Hikal Limited (HIKAL) Q2 FY27 Financial Results: PAT ₹-7 & Revenue ₹403 Cr

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
MetricValue
Revenue₹403 Cr
Net Profit (PAT)₹-7
📢 Key Event
Hikal reports Q1 FY27 revenue of ₹403 crores and net loss of ₹7 crores amid remediation costs.
🔄 What Changed
Net debt reduced from ₹815 crores to ₹685 crores; EBITDA margin at 9.2% with ₹9 crores exceptional income.
🔮 What's Next
15-16% FY27 revenue growth; Animal Health targeting Rs. 400 crores by FY30 with >20% EBITDA margins.
💡 Investor Takeaway
The company is strategically shifting toward pharma and Animal Health while managing remediation costs and debt reduction.

Hikal Limited reported Q1 FY27 revenue of ₹403 crores with an EBITDA margin of 9.2%, posting a net loss of [amount context mismatch] crores due to remediation costs, though exceptional income of ₹9 crores reversed prior provisions. Capital expenditure reached ₹45 crores, debt declined to ₹685 crores, and EcoVadis recognition underscores sustainability leadership. Pharma revenue grew to ₹233 crores with 3.2% EBIT, while crop protection faced margin pressure. Management targets 15-16% FY27 revenue growth, 20%+ EBITDA margins in Animal Health, and Rs. 400 crores revenue by FY30, supported by capacity expansion and regulatory progress.

📄 View Original Announcement (PDF)

About Hikal Limited (HIKAL)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹2,484.02 Cr P/E: 33.4

View full HIKAL stock details →

📡 Get AI alerts when HIKAL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track HIKAL — Free

📊 More HIKAL filings

See all HIKAL filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when HIKAL files new disclosures

Track HIKAL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HIKAL — Free

Free account · 2 AI queries/day